U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institute of Allergy and Infectious Diseases (NIAID)
For Immediate Release: Thursday, October 21, 2021
Media Contact: Ken Pekoc, (301) 402-1663, <e-mail:kpekoc@xxxxxxxxxxxxx>
MEDIA AVAILABILITY
COVID VACCINE BOOSTER INCREASES ANTIBODY RESPONSES, IS PROTECTIVE IN RHESUS MACAQUES
Different mRNA-1273 boosters are equally protective against variants
WHAT:
A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues. The study, published in Science, also showed that the increased neutralizing antibody responses were sustained for at least eight weeks after the boost, were significantly higher than after the primary vaccine series, and generated high-level protection - meaning the ability to significantly limit virus from replicating in the lungs and nose. These data suggest that boosting triggers a strong immune memory response and potentially longer lasting immunity.
The researchers also determined that both the mRNA-1273 vaccine developed to target the original SARS-CoV-2 virus and a slightly modified version of the vaccine targeting the Beta variant, were equivalent in their ability to boost antibody responses and protect. Scientists at the Vaccine Research Center, part of NIH's National Institute of Allergy and Infectious Diseases, led the project with collaborators from Emory University; Bioqual, Inc.; Moderna, Inc.; and Johns Hopkins University.
This study was performed six months ago when the SARS-CoV-2 Beta variant was a major concern. The researchers focused on the Beta variant because it has consistently shown the greatest ability to resist neutralization - by likely reducing vaccine effectiveness - according to the researchers. While Delta has become the dominant virus variant in the United States, because of its high transmissibility, it has only an intermediate ability to resist neutralization, the study authors state.
The scientists write that in people, an mRNA-1273 booster vaccine may improve the duration and potency of protection against upper and lower airway infection by any of the circulating SARS-CoV-2 variants, including Delta. They note that this would be especially important to maintain protection against severe disease and possibly limit mild infection and virus transmission. Their results support vaccine boosting in the elderly, people with pre-existing health conditions, those at high-risk exposure, and those who responded poorly to primary vaccination.
ARTICLE:
K Corbett, et al. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Vaccine Boosted Nonhuman Primates <https://www.science.org/doi/10.1126/science.abl8912>. Science DOI: 10.1126/science.abl8912 (2021).
WHO:
Robert A. Seder, M.D., chief of NIAID's Cellular Immunology Section in the Vaccine Research Center, is available to discuss this study.
CONTACT
To schedule interviews, please contact Ken Pekoc, (301) 402-1663, kpekoc@xxxxxxxxxxxxx.
NIAID conducts and supports research-at NIH, throughout the United States, and worldwide-to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website <https://www.niaid.nih.gov/>.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <www.nih.gov>.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
###
This NIH News Release is available online at:
<https://www.nih.gov/news-events/news-releases/covid-vaccine-booster-increases-antibody-responses-protective-rhesus-macaques>
To subscribe (or unsubscribe) from NIH News Release mailings, go to
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>.
